Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 10,000 shares at $27.48 ($274K) on 2021-04-01, disclosed to the SEC on 2021-04-05.
Open-market sale of $274k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.22 | 700 | $18K | 6.7% |
| 2 | $27.48 | 8,500 | $234K | 85.1% |
| 3 | $28.11 | 800 | $22K | 8.2% |
| Total | $27.44 avg | 10,000 | $274K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |